Dear Doctor, we kindly request your participation in a short pre-meeting survey. This survey will help us ensure that the forum covers relevant topics aligned with your expertise and interests. The survey will only take a few minutes to complete. Thank you for your commitment to this forum, and we look forward to receiving your survey responses.

Q1. What are the top 3 challenges or concerns that you face in NDD (Non-dialysis-dependent) and DD (Dialysis-dependent) patient with CKD anaemia. Please select 3 options. 
Q2. At what Hb level do you initiate ESA treatment in NDD (Non-dialysis-dependent) patients with anaemia of CKD, assuming the patient is iron replete?

Q3. Please indicate the top 3 challenges you face with ESA therapy in NDD (Non-dialysis-dependent) patients with anaemia of CKD. Please select 3 options.

Q4. At what Hb level do you initiate ESA treatment in DD (Dialysis-dependent) patients with anaemia of CKD, assuming the patient is iron replete?

Q5. Please indicate the top 3 challenges you face with ESA therapy in DD (Dialysis-dependent) patients with anaemia of CKD. Please select 3 options.

Q6. In patients at high risk of CKD, such as those with T2DM, HTN, or CV risks, is checking for urine albumin a routine practice in your clinical setting?
Q7. According to the 2019/20 Hospital Authority Diabetes Mellitus Care Report, urine albumin testing rate is only around 60% in DM populations in Hong Kong, what are the THREE key challenges for urine albumin testing?

Reference: https://www.ha.org.hk/haho/ho/icp/HA_DM_Care_Report1920_en_txt.pdf
Q8. Which of the following strategies do you think would best optimise the adoption of the KDIGO 2024 recommendations for SGLT2 inhibitors as first-line treatment and regular uACR testing for patients in Hong Kong? (Select all that apply)

HK-10672 08/08/2024